{
    "id": 1217,
    "fullName": "MET positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MET positive indicates the presence of the MET gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4233,
        "geneSymbol": "MET",
        "terms": [
            "MET",
            "AUTS9",
            "c-Met",
            "DFNB97",
            "HGFR",
            "RCCP2"
        ]
    },
    "variant": "positive",
    "createDate": "07/30/2014",
    "updateDate": "08/09/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9983,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, ABBV-399 was well-tolerated and demonstrated preliminary efficacy in patients with MET-positive non-small cell lung cancer, with 30% (3/10) of patients demonstrating a partial response (J Clin Oncol 34, 2016 (suppl; abstr 2510)).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 1363,
                "therapyName": "Telisotuzumab vedotin",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7834,
                    "pubMedId": null,
                    "title": "Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.",
                    "url": "http://meetinglibrary.asco.org/content/164513-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1011,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Merestinib (LY2801653) treatment resulted in growth inhibition correlating with Met expression level in a panel of patient-derived xenograft models of solid tumors (Cancer Res 2010;70(8 Suppl):Abstract nr 3611).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 1030,
                "therapyName": "Merestinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 729,
                    "pubMedId": null,
                    "title": "LY2801653, an orally available small molecule inhibitor of c-Met, demonstrated broad antitumor efficacy in patient derived xenograft models",
                    "url": "http://cancerres.aacrjournals.org/content/70/8_Supplement/3611"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7063,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 19% (5/26) of MET-positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6064,
                    "pubMedId": null,
                    "title": "Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).",
                    "url": "http://meetinglibrary.asco.org/content/165406-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7041,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Altiratinib (DCC-2701) inhibited viability of several MET-expressing glioblastoma cell lines in culture and inhibited tumor growth in cell line xenograft models (PMID: 26965451).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 1656,
                "therapyName": "Altiratinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6048,
                    "pubMedId": 26965451,
                    "title": "Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26965451"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9984,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, INCB028060 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, as indicated by decreased whole blood Met phosphorylation level (J Clin Oncol 29: 2011 (suppl; abstr 3091)).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 776,
                "therapyName": "INCB028060",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7835,
                    "pubMedId": null,
                    "title": "A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors.",
                    "url": "http://meetinglibrary.asco.org/content/82236-102"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12649,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Met expression and mutation status were not associated with response to AMG208 treatment in patients with advanced solid tumor (PMID: 26155941; NCT00813384).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 630,
                "therapyName": "AMG208",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10534,
                    "pubMedId": 26155941,
                    "title": "A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26155941"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1644,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Altiratinib (DCC-2701) inhibited MET activation, decreased viability and migration of c-MET positive ovarian cancer cells in culture, and reduced tumor growth in ovarian cancer cell line xenograft models (PMID: 24362531).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 1656,
                "therapyName": "Altiratinib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1757,
                    "pubMedId": 24362531,
                    "title": "Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24362531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7040,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Altiratinib (DCC-2701) and Avastin (bevacizumab) inhibited tumor growth and invasiveness, decreased blood vessel formation, and prolonged survival in cell line xenograft models of MET-expressing glioblastoma (PMID: 26965451).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 4353,
                "therapyName": "Altiratinib + Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6048,
                    "pubMedId": 26965451,
                    "title": "Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26965451"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19621,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HS10241 inhibited phosphorylation of Met and Parp, and reduced survival of MET-positive high-grade serous ovarian cancer cell lines in culture (PMID: 30949414).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 9102,
                "therapyName": "HS10241",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17305,
                    "pubMedId": 30949414,
                    "title": "Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30949414"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9975,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Ficlatuzumab treatment resulted in stable disease in 57% (12/21) of patients with advanced solid tumors and a decrease in phosphorylated Met in one patient with multiple myeloma (PMID: 24901237).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 740,
                "therapyName": "Ficlatuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7832,
                    "pubMedId": 24901237,
                    "title": "Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24901237"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10639,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Emibetuzumab (LY2875358) and Tarceva (erlotinib) combination treatment resulted in durable partial response in 14.3% (2/14) of patients with non-small cell lung carcinoma, with both responders being Met positive (PMID: 27803065).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 1179,
                "therapyName": "Emibetuzumab + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8681,
                    "pubMedId": 27803065,
                    "title": "A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27803065"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9972,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Emibetuzumab (LY2875358) and Tarceva (erlotinib) combination treatment resulted in durable partial response in 15% (2/13) of Met-positive patients with non-small cell lung carcinoma (J Clin Oncol 31, 2013 (suppl; abstr 8093)).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 1179,
                "therapyName": "Emibetuzumab + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7831,
                    "pubMedId": null,
                    "title": "First-in-human dose escalation study of LY2875358 (LY), a bivalent MET antibody, as monotherapy and in combination with erlotinib (E) in patients with advanced cancer.",
                    "url": "http://meetinglibrary.asco.org/content/115545-132"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10414,
            "approvalStatus": "Phase II",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a Phase II trial, higher baseline soluble Met level correlated with longer overall survival in cholangiocarcinoma patients treated with Cometriq (cabozantinib) (PMID: 28192597).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8428,
                    "pubMedId": 28192597,
                    "title": "A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28192597"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20684,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Capmatinib (INC280) treatment resulted in a best overall response of stable disease in 26% (10/38) of patients with MET-positive advanced solid tumors including gastric cancer and hepatocellular carcinoma, and two patients demonstrated tumor reduction (PMID: 31778267; NCT01324479).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17987,
                    "pubMedId": 31778267,
                    "title": "Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31778267"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6225,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) inhibited Met activity, cell growth, and invasive cellular characteristics in a human MET positive TNBC cell line in culture, and reduced tumor volume in xenograft models (PMID: 26432786).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5492,
                    "pubMedId": 26432786,
                    "title": "Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432786"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19620,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HS10241 inhibited phosphorylation of Met and Parp, and reduced survival of MET-positive triple-negative breast cancer cell lines in culture (PMID: 30949414).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 9102,
                "therapyName": "HS10241",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17305,
                    "pubMedId": 30949414,
                    "title": "Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30949414"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19623,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HS10241 and Fluzoparib combination treatment synergistically induced DNA-damage in MET and PARP-positive high-grade serous ovarian cancer cell lines in culture (PMID: 30949414).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 9103,
                "therapyName": "Fluzoparib + HS10241",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17305,
                    "pubMedId": 30949414,
                    "title": "Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30949414"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1769,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Onartuzumab (RO5490258), in combination with Tarceva (erlotinib) demonstrated efficacy in patients with Met-positive NSCLC (PMID: 24101053). However, a subsequent Phase III clinical trial has been unable to confirm this efficacy (J Clin Oncol 32:5s, 2014 (suppl; abstr 8000)).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 1280,
                "therapyName": "Erlotinib + Onartuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 2030,
                    "pubMedId": 24101053,
                    "title": "Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24101053"
                },
                {
                    "id": 2031,
                    "pubMedId": null,
                    "title": "Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial.",
                    "url": "http://meetinglibrary.asco.org/content/128045-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9969,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ARGX-111 demonstrated safety and resulted in some efficacy in patients with advanced solid tumors expressing MET, including a decrease in circulating tumor cells positive for MET (Journal of Clinical Oncology 33, no. 15_suppl, May 2015, 2580-2580).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 2157,
                "therapyName": "ARGX-111",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7830,
                    "pubMedId": null,
                    "title": "A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors",
                    "url": "http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.2580"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9971,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Emibetuzumab (LY2875358) treatment resulted in durable partial response in 4% (1/23) of Met-positive patients with advanced solid tumors (J Clin Oncol 31, 2013 (suppl; abstr 8093)).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 803,
                "therapyName": "Emibetuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7831,
                    "pubMedId": null,
                    "title": "First-in-human dose escalation study of LY2875358 (LY), a bivalent MET antibody, as monotherapy and in combination with erlotinib (E) in patients with advanced cancer.",
                    "url": "http://meetinglibrary.asco.org/content/115545-132"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18539,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, Emibetuzumab (LY2875358) and Cyramza (ramucirumab) combination treatment resulted in an objective response rate of 6.7% (3/45) and a disease control rate of 60% (27/45) in patients with hepatocellular carcinoma, with a median progression-free survival (mPFS) of 5.4 months, patients with MET expression of 2+ or above in over 50% of tumor cells (n=19) demonstrated improved mPFS (8.1 vs 2.8 mo, HR=0.22) compared to patients below the cut-off (n=14) (PMID: 31142504; NCT02082210).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 1387,
                "therapyName": "Emibetuzumab + Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16219,
                    "pubMedId": 31142504,
                    "title": "A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31142504"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19622,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HS10241 and Fluzoparib combination treatment synergistically induced DNA-damage in MET and PARP-positive triple-negative breast cancer cell lines in culture (PMID: 30949414).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 9103,
                "therapyName": "Fluzoparib + HS10241",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17305,
                    "pubMedId": 30949414,
                    "title": "Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30949414"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1756,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Amuvatinib (MP470) demonstrated efficacy in reducing Met phosphorylation and inducing apoptosis in cultured myeloma cells (PMID: 24326130).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 632,
                "therapyName": "Amuvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 70004,
                "name": "myeloid neoplasm",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2025,
                    "pubMedId": 24326130,
                    "title": "Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24326130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12576,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (CREATE), Xalkori (crizotinib) treatment in MET-positive clear cell sarcoma patients resulted in an objective response rate of 3.8% (1/26) and a median progression-free survival of 131 days, similar to results achieved with first-line Adriamycin (doxorubicin) in non-selected metastatic soft tissue sarcomas (PMID: 28950372; NCT01524926).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 4233,
                "name": "clear cell sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10454,
                    "pubMedId": 28950372,
                    "title": "Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28950372"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14960,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ningetinib inhibited Met phosphorylation in tumor tissue, resulted in prolonged median survival time and significantly increased life-span in cell line xenograft models of glioblastoma (Cancer Res 2014;74(19 Suppl):Abstract nr 1755).",
            "molecularProfile": {
                "id": 1240,
                "profileName": "MET positive"
            },
            "therapy": {
                "id": 7232,
                "therapyName": "Ningetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11861,
                    "pubMedId": null,
                    "title": "CT053PTSA, a novel c-MET and VEGFR2 inhibitor, potently suppresses angiogenesis and tumor growth",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/1755"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10904,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).",
            "molecularProfile": {
                "id": 26426,
                "profileName": "ERBB2 neg MET pos"
            },
            "therapy": {
                "id": 5676,
                "therapyName": "Fluorouracil + Leucovorin + Onartuzumab + Oxaliplatin",
                "synonyms": "Onartuzumab + FOLFOX"
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8918,
                    "pubMedId": 27918764,
                    "title": "Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27918764"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10905,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).",
            "molecularProfile": {
                "id": 26426,
                "profileName": "ERBB2 neg MET pos"
            },
            "therapy": {
                "id": 5676,
                "therapyName": "Fluorouracil + Leucovorin + Onartuzumab + Oxaliplatin",
                "synonyms": "Onartuzumab + FOLFOX"
            },
            "indication": {
                "id": 4914,
                "name": "esophagus adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8918,
                    "pubMedId": 27918764,
                    "title": "Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27918764"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8744,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).",
            "molecularProfile": {
                "id": 26426,
                "profileName": "ERBB2 neg MET pos"
            },
            "therapy": {
                "id": 629,
                "therapyName": "Rilotumumab",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6729,
                    "pubMedId": null,
                    "title": "Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal juncti",
                    "url": "http://meetinglibrary.asco.org/content/147255-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8746,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).",
            "molecularProfile": {
                "id": 26426,
                "profileName": "ERBB2 neg MET pos"
            },
            "therapy": {
                "id": 838,
                "therapyName": "Onartuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6730,
                    "pubMedId": null,
                    "title": "METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).",
                    "url": "http://meetinglibrary.asco.org/content/147779-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8747,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).",
            "molecularProfile": {
                "id": 26426,
                "profileName": "ERBB2 neg MET pos"
            },
            "therapy": {
                "id": 838,
                "therapyName": "Onartuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6730,
                    "pubMedId": null,
                    "title": "METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).",
                    "url": "http://meetinglibrary.asco.org/content/147779-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8745,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).",
            "molecularProfile": {
                "id": 26426,
                "profileName": "ERBB2 neg MET pos"
            },
            "therapy": {
                "id": 629,
                "therapyName": "Rilotumumab",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6729,
                    "pubMedId": null,
                    "title": "Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal juncti",
                    "url": "http://meetinglibrary.asco.org/content/147255-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10064,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Altiratinib (DCC-701) increased survival in a MET and HGF-expressing glioblastoma cell line xenograft model (PMID: 26285778).",
            "molecularProfile": {
                "id": 27233,
                "profileName": "HGF pos MET pos"
            },
            "therapy": {
                "id": 1656,
                "therapyName": "Altiratinib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7263,
                    "pubMedId": 26285778,
                    "title": "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26285778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10065,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Altiratinib (DCC-701) and Avastin (bevacizumab) resulted in decreased tumor growth, increased survival, and a decrease in TIE2-expressing circulating monocytes in a MET and HGF-expressing glioblastoma cell line xenograft model (PMID: 26285778).",
            "molecularProfile": {
                "id": 27233,
                "profileName": "HGF pos MET pos"
            },
            "therapy": {
                "id": 4353,
                "therapyName": "Altiratinib + Bevacizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7263,
                    "pubMedId": 26285778,
                    "title": "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26285778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12259,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGFR1-amplified lung cancer cell lines with Met expression were resistant to AZD4547 in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28614,
                "profileName": "FGFR1 amp MET pos"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12262,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FGFR1-amplified lung cancer cell lines with Met expression were resistant to Rogaratinib (BAY 1163877) in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28614,
                "profileName": "FGFR1 amp MET pos"
            },
            "therapy": {
                "id": 890,
                "therapyName": "Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17899,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, patients with MET-positive non-small lung cancer harboring either EGFR L858R or an EGFR exon 19 deletion demonstrated a median progression-free survival of 8.9 mo., median overall survival of 15.6 mo., and an overall response rate of 68.9% (all partial responses) following first-line therapy with Tarceva (erlotinib) and Onartuzumab; however, the trial was terminated early due to lack of efficacy with the therapy in another trial and thus, the results are not conclusive (PMID: 30472556).",
            "molecularProfile": {
                "id": 32878,
                "profileName": "EGFR exon 19 del MET pos"
            },
            "therapy": {
                "id": 1280,
                "therapyName": "Erlotinib + Onartuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 15862,
                    "pubMedId": 30472556,
                    "title": "First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30472556"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17900,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, patients with MET-positive non-small lung cancer harboring either EGFR L858R or an EGFR exon 19 deletion demonstrated a median progression-free survival of 8.9 mo., median overall survival of 15.6 mo., and an overall response rate of 68.9% (all partial responses) following first-line therapy with Tarceva (erlotinib) and Onartuzumab; however, the trial was terminated early due to lack of efficacy with the therapy in another trial and thus, the results are not conclusive (PMID: 30472556).",
            "molecularProfile": {
                "id": 32879,
                "profileName": "EGFR L858R MET pos"
            },
            "therapy": {
                "id": 1280,
                "therapyName": "Erlotinib + Onartuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 15862,
                    "pubMedId": 30472556,
                    "title": "First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30472556"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1240,
            "profileName": "MET positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26426,
            "profileName": "ERBB2 neg MET pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27233,
            "profileName": "HGF pos MET pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28614,
            "profileName": "FGFR1 amp MET pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28759,
            "profileName": "EWSR1 - ATF1 MET pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29436,
            "profileName": "TFE3 fusion MET pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32878,
            "profileName": "EGFR exon 19 del MET pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32879,
            "profileName": "EGFR L858R MET pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}